{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:15:43Z","timestamp":1791281743109,"version":"4.1.0"},"reference-count":47,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,5,1]]},"abstract":"<jats:p>Objective. Recent reports warn that the worldwide cell culture capacity is insufficient to fulfill the increasing demand for human protein drugs. Production in milk of transgenic animals is an attractive alternative. Kilogram quantities of product per year can be obtained at relatively low costs, even in small animals such as rabbits. We tested the long-term safety and efficacy of recombinant human \u03b1-glucosidase (rhAGLU) from rabbit milk for the treatment of the lysosomal storage disorder Pompe disease. The disease occurs with an estimated frequency of 1 in 40 000 and is designated as orphan disease. The classic infantile form leads to death at a median age of 6 to 8 months and is diagnosed by absence of \u03b1-glucosidase activity and presence of fully deleterious mutations in the \u03b1-glucosidase gene. Cardiac hypertrophy is characteristically present. Loss of muscle strength prevents infants from achieving developmental milestones such as sitting, standing, and walking. Milder forms of the disease are associated with less severe mutations and partial deficiency of \u03b1-glucosidase.<\/jats:p>\n               <jats:p>Methods. In the beginning of 1999, 4 critically ill patients with infantile Pompe disease (2.5\u20138 months of age) were enrolled in a single-center open-label study and treated intravenously with rhAGLU in a dose of 15 to 40 mg\/kg\/week.<\/jats:p>\n               <jats:p>Results. Genotypes of patients were consistent with the most severe form of Pompe disease. Additional molecular analysis failed to detect processed forms of \u03b1-glucosidase (95, 76, and 70 kDa) in 3 of the 4 patients and revealed only a trace amount of the 95-kDa biosynthetic intermediate form in the fourth (patient 1). With the more sensitive detection method, 35S-methionine incorporation, we could detect low-level synthesis of \u03b1-glucosidase in 3 of the 4 patients (patients 1, 2, and 4) with some posttranslation modification from 110 kDa to 95 kDa in 1 of them (patient 1). One patient (patient 3) remained totally deficient with both detection methods (negative for cross-reactive immunologic material [CRIM negative]). The \u03b1-glucosidase activity in skeletal muscle and fibroblasts of all 4 patients was below the lower limit of detection (&amp;lt;2% of normal). The rhAGLU was tolerated well by the patients during &amp;gt;3 years of treatment. Anti-rhAGLU immunoglobulin G titers initially increased during the first 20 to 48 weeks of therapy but declined thereafter. There was no consistent difference in antibody formation comparing CRIM-negative with CRIM-positive patients. Muscle \u03b1-glucosidase activity increased from &amp;lt;2% to 10% to 20% of normal in all patients during the first 12 weeks of treatment with 15 to 20 mg\/kg\/week. For optimizing the effect, the dose was increased to 40 mg\/kg\/week. This resulted, 12 weeks later, in normal \u03b1-glucosidase activity levels, which were maintained until the last measurement in week 72. Importantly, all 4 patients, including the patient without any endogenous \u03b1-glucosidase (CRIM negative), revealed mature 76- and 70-kDa forms of \u03b1-glucosidase on Western blot. Conversion of the 110-kDa precursor from milk to mature 76\/70-kDa \u03b1-glucosidase provides evidence that the enzyme is targeted to lysosomes, where this proteolytic processing occurs. At baseline, patients had severe glycogen storage in the quadriceps muscle as revealed by strong periodic acid-Schiff\u2014positive staining and lacework patterns in hematoxylin and eosin\u2014stained tissue sections. The muscle pathology correlated at each time point with severity of signs. Periodic acid-Schiff intensity diminished and number of vacuoles increased during the first 12 weeks of treatment. Twelve weeks after dose elevation, we observed signs of muscle regeneration in 3 of the 4 patients. Obvious improvement of muscular architecture was seen only in the patient who learned to walk. Clinical effects were significant. All patients survived beyond the age of 4 years, whereas untreated patients succumb at a median age of 6 to 8 months. The characteristic cardiac hypertrophy present at start of treatment diminished significantly. The left ventricular mass index decreased from 171 to 599 g\/m2 (upper limit of normal 86.6 g\/m2 for infants from 0 to 1 year) to 70 to 160 g\/m2 during 84 weeks of treatment. In addition, we found a significant change of slope for the diastolic thickness of the left ventricular posterior wall against time at t = 0 for each separate patient. Remarkably, the younger patients (patients 1 and 3) showed no significant respiratory problems during the first 2 years of life. One of the younger patients recovered from a life-threatening bronchiolitis at the age of 1 year without sequelae, despite borderline oxygen saturations at inclusion. At the age of 2, however, she became ventilator dependent after surgical removal of an infected Port-A-Cath. She died at the age of 4 years and 3 months suddenly after a short period of intractable fever of &amp;gt;42\u00b0C, unstable blood pressure, and coma. The respiratory course of patient 1 remained uneventful. The 2 older patients, who both were hypercapnic (partial pressure of carbon dioxide: 10.6 and 9.8 kPa; normal range: 4.5-6.8 kPa) at start of treatment, became ventilator dependent before the first infusion (patient 2) and after 10 weeks of therapy (patient 4). Patient 4 was gradually weaned from the ventilator after 1 year of high-dose treatment and was eventually completely ventilator-free for 5 days, but this situation could not be maintained. Currently, both patients are completely ventilator dependent. The most remarkable progress in motor function was seen in the younger patients (patients 1 and 3). They achieved motor milestones that are unmet in infantile Pompe disease. Patient 1 learned to crawl (12 months), walk (16 months), squat (18 months), and climb stairs (22 months), and patient 3 learned to sit unsupported. The Alberta Infant Motor Scale score for patients 2, 3, and 4 remained far below p5. Patient 1 followed the p5 of normal.<\/jats:p>\n               <jats:p>Conclusion. Our study shows that a safe and effective medicine can be produced in the milk of mammals and encourages additional development of enzyme replacement therapy for the several forms of Pompe disease. Restoration of skeletal muscle function and prevention of pulmonary insufficiency require dosing in the range of 20 to 40 mg\/kg\/week. The effect depends on residual muscle function at the start of treatment. Early start of treatment is required.<\/jats:p>","DOI":"10.1542\/peds.113.5.e448","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:53:04Z","timestamp":1092444784000},"page":"e448-e457","source":"Crossref","is-referenced-by-count":295,"title":["Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human \u03b1-Glucosidase From Milk"],"prefix":"10.1542","volume":"113","author":[{"given":"Johanna M.P.","family":"Van den Hout","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC-Sophia, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep H.J.","family":"Kamphoven","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC-Sophia, Rotterdam, Rotterdam, The Netherlands"},{"name":"Department of Clinical Genetics, Erasmus MC, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le\u0301on P.F.","family":"Winkel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC-Sophia, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem F.M.","family":"Arts","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurology, Erasmus MC-Sophia, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes B.C. De","family":"Klerk","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC-Sophia, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Christa B.","family":"Loonen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurology, Erasmus MC-Sophia, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold G.","family":"Vulto","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Erasmus MC, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri","family":"Cromme-Dijkhuis","sequence":"additional","affiliation":[{"name":"Division of Pediatric Cardiology, Erasmus MC-Sophia, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke","family":"Weisglas-Kuperus","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Erasmus MC-Sophia, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Hop","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Van","family":"Hirtum","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Erasmus MC, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto P. Van","family":"Diggelen","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Erasmus MC, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Boer","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Erasmus MC, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian A.","family":"Kroos","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Erasmus MC, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A. Van","family":"Doorn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erasmus MC, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin Van der","family":"Voort","sequence":"additional","affiliation":[{"name":"Division of Pediatric Intensive Care, Erasmus MC-Sophia, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sibbles","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Erasmus MC-Sophia, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel J.J.M. Van","family":"Corven","sequence":"additional","affiliation":[{"name":"Pharming-Genzyme LLC, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Just P.J.","family":"Brakenhoff","sequence":"additional","affiliation":[{"name":"Pharming-Genzyme LLC, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan Van","family":"Hove","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Hospital Gasthuisberg, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.M.","family":"Smeitink","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Metabolic Diseases, University Medical Center Nijmegen, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard de","family":"Jong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus MC, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold J.J.","family":"Reuser","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Erasmus MC, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T. Van der","family":"Ploeg","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC-Sophia, Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2004,5,1]]},"reference":[{"key":"2021121010073473000_R1","doi-asserted-by":"crossref","unstructured":"Mynahan R, Anderson R. The protein production challenge. In vivo. Bus Med Rep.\u20082001;72","DOI":"10.1016\/S0301-6226(01)00266-4"},{"key":"2021121010073473000_R2","doi-asserted-by":"crossref","unstructured":"Janne J, Alhonen L, Hyttinen JM, Peura T, Tolvanen M, Korhonen VP. Transgenic bioreactors. Biotechnol Annu Rev.\u20081998;4:55\u201374","DOI":"10.1016\/S1387-2656(08)70067-X"},{"key":"2021121010073473000_R3","doi-asserted-by":"crossref","unstructured":"Simons JP, Wilmut I, Clark AJ, Archibald AL, Bishof JO, Lathe R. Gene transfer into sheep. Biotechnology.\u20081988;6:113\u2013120","DOI":"10.1038\/nbt0288-179"},{"key":"2021121010073473000_R4","doi-asserted-by":"crossref","unstructured":"McKee C, Gibson A, Dalrymple M, Emslie L, Garner I, Cottingham I. Production of biologically active salmon calcitonin in the milk of transgenic rabbits. Nat Biotechnol.\u20081998;16:647\u2013651","DOI":"10.1038\/nbt0798-647"},{"key":"2021121010073473000_R5","doi-asserted-by":"crossref","unstructured":"Niemann H, Halter R, Carnwath JW, Herrmann D, Lemme E, Paul D. Expression of human blood clotting factor VIII in the mammary gland of transgenic sheep. Transgenic Res.\u20081999;8:237\u2013247","DOI":"10.1023\/A:1008999622117"},{"key":"2021121010073473000_R6","doi-asserted-by":"crossref","unstructured":"Paleyanda RK, Velander WH, Lee TK, et al. Transgenic pigs produce functional human factor VIII in milk. Nat Biotechnol.\u20081997;15:971\u2013975","DOI":"10.1038\/nbt1097-971"},{"key":"2021121010073473000_R7","doi-asserted-by":"crossref","unstructured":"Van Berkel PH, Welling MM, Geerts M, et al. Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nat Biotechnol.\u20082002;20:484\u2013487","DOI":"10.1038\/nbt0502-484"},{"key":"2021121010073473000_R8","doi-asserted-by":"crossref","unstructured":"Lu W, Mant T, Levy JH, Bailey JM. Pharmacokinetics of recombinant transgenic antithrombin in volunteers. Anesth Analg.\u20082000;90:531\u2013534","DOI":"10.1097\/00000539-200003000-00006"},{"key":"2021121010073473000_R9","doi-asserted-by":"crossref","unstructured":"Carver AS, Dalrymple MA, Wright G, et al. Transgenic livestock as bioreactors: stable expression of human alpha-1-antitrypsin by a flock of sheep. Biotechnology.\u20081993;11:1263\u20131270","DOI":"10.1038\/nbt1193-1263"},{"key":"2021121010073473000_R10","doi-asserted-by":"crossref","unstructured":"Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet.\u20082000;356:397\u2013398","DOI":"10.1016\/S0140-6736(00)02533-2"},{"key":"2021121010073473000_R11","doi-asserted-by":"crossref","unstructured":"van den Hout JMP, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature. Pediatrics.\u20082003;112:332\u2013340","DOI":"10.1542\/peds.112.2.332"},{"key":"2021121010073473000_R12","unstructured":"Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet A, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:3389\u20133420"},{"key":"2021121010073473000_R13","doi-asserted-by":"crossref","unstructured":"Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr.\u20082000;137:283\u2013285","DOI":"10.1067\/mpd.2000.107112"},{"key":"2021121010073473000_R14","doi-asserted-by":"crossref","unstructured":"Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet.\u20081999;7:713\u2013716","DOI":"10.1038\/sj.ejhg.5200367"},{"key":"2021121010073473000_R15","doi-asserted-by":"crossref","unstructured":"Martiniuk F, Chen A, Mack A, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet.\u20081998;79:69\u201372","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K"},{"key":"2021121010073473000_R16","doi-asserted-by":"crossref","unstructured":"Van der Ploeg AT, Van der Kraaij AM, Willemsen R, et al. Rat heart perfusion as model system for enzyme replacement therapy in glycogenosis type II. Pediatr Res.\u20081990;28:344\u2013347","DOI":"10.1203\/00006450-199010000-00009"},{"key":"2021121010073473000_R17","doi-asserted-by":"crossref","unstructured":"Van der Ploeg AT, Kroos MA, Willemsen R, Brons NH, Reuser AJ. Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. J Clin Invest.\u20081991;87:513\u2013518","DOI":"10.1172\/JCI115025"},{"key":"2021121010073473000_R18","doi-asserted-by":"crossref","unstructured":"Bijvoet AG, Kroos MA, Pieper FR, et al. Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum Mol Genet.\u20081998;7:1815\u20131824","DOI":"10.1093\/hmg\/7.11.1815"},{"key":"2021121010073473000_R19","doi-asserted-by":"crossref","unstructured":"Bijvoet AG, Van Hirtum H, Kroos MA, et al. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet.\u20081999;8:2145\u20132153","DOI":"10.1093\/hmg\/8.12.2145"},{"key":"2021121010073473000_R20","doi-asserted-by":"crossref","unstructured":"De Duve C, Wattiaux R. Functions of lysosomes. Annu Rev Physiol.\u20081966;28:435\u2013492","DOI":"10.1146\/annurev.ph.28.030166.002251"},{"key":"2021121010073473000_R21","doi-asserted-by":"crossref","unstructured":"Hoefsloot LH, Hoogeveen-Westerveld M, Kroos MA, Van Beeumen J, Reuser AJ, Oostra BA. Primary structure and processing of lysosomal alpha-glucosidase: homology with the intestinal sucrase-isomaltase complex. EMBO J.\u20081988;7:1697\u20131704","DOI":"10.1002\/j.1460-2075.1988.tb02998.x"},{"key":"2021121010073473000_R22","doi-asserted-by":"crossref","unstructured":"Martiniuk F, Mehler M, Tzall S, Meredith G, Hirschhorn R. Sequence of the cDNA and 5\u2032-flanking region for human acid alpha-glucosidase, detection of an intron in the 5\u2032 untranslated leader sequence, definition of 18-bp polymorphisms, and differences with previous cDNA and amino acid sequences. DNA Cell Biol.\u20081990;9:85\u201394","DOI":"10.1089\/dna.1990.9.85"},{"key":"2021121010073473000_R23","doi-asserted-by":"crossref","unstructured":"Hoefsloot LH, Hoogeveen-Westerveld M, Reuser AJ, Oostra BA. Characterization of the human lysosomal alpha-glucosidase gene. Biochem J.\u20081990;272:493\u2013497","DOI":"10.1042\/bj2720493"},{"key":"2021121010073473000_R24","doi-asserted-by":"crossref","unstructured":"Fuller M, Van der Ploeg A, Reuser AJ, Anson DS, Hopwood JJ. Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase. Eur J Biochem.\u20081995;234:903\u2013909","DOI":"10.1111\/j.1432-1033.1995.903_a.x"},{"key":"2021121010073473000_R25","doi-asserted-by":"crossref","unstructured":"Bijvoet AG, Kroos MA, Pieper FR, et al. Expression of cDNA-encoded human acid alpha-glucosidase in milk of transgenic mice. Biochim Biophys Acta.\u20081996;1308:93\u201396","DOI":"10.1016\/0167-4781(96)00093-0"},{"key":"2021121010073473000_R26","unstructured":"Reuser AJ, Koster JF, Hoogeveen A, Galjaard H. Biochemical, immunological, and cell genetic studies in glycogenosis type II. Am J Hum Genet.\u20081978;30:132\u2013143"},{"key":"2021121010073473000_R27","doi-asserted-by":"crossref","unstructured":"Hermans MM, Kroos MA, Smeitink JA, van der Ploeg AT, Kleijer WJ, Reuser AJ. Glycogen storage disease type II: genetic and biochemical analysis of novel mutations in infantile patients from Turkish ancestry. Hum Mutat.\u20081998;11:209\u2013215","DOI":"10.1002\/(SICI)1098-1004(1998)11:3<209::AID-HUMU5>3.0.CO;2-C"},{"key":"2021121010073473000_R28","doi-asserted-by":"crossref","unstructured":"Reuser AJ, Kroos M, Oude Elferink RP, Tager JM. Defects in synthesis, phosphorylation, and maturation of acid alpha-glucosidase in glycogenosis type II. J Biol Chem.\u20081985;260:8336\u20138341","DOI":"10.1016\/S0021-9258(17)39477-2"},{"key":"2021121010073473000_R29","doi-asserted-by":"crossref","unstructured":"Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation.\u20081978;58:1072\u20131083","DOI":"10.1161\/01.CIR.58.6.1072"},{"key":"2021121010073473000_R30","doi-asserted-by":"crossref","unstructured":"Devereux RB, Casale PN, Kligfield P, et al. Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy. Am J Cardiol.\u20081986;57:1388\u20131393","DOI":"10.1016\/0002-9149(86)90224-9"},{"key":"2021121010073473000_R31","unstructured":"Piper MC, Darrah J. Motor Assessment of the Developing Infant. Philadelphia, PA: WB Saunders Company; 1994"},{"key":"2021121010073473000_R32","unstructured":"Bayley N. Bayley Scales of Infant Development. 2nd ed. San Antonio, TX: Harcourt Brace & Company; 1993"},{"key":"2021121010073473000_R33","doi-asserted-by":"crossref","unstructured":"Van Hove JL, Yang HW, Wu JY, Brady RO, Chen YT. High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Proc Natl Acad Sci U S A.\u20081996;93:65\u201370","DOI":"10.1073\/pnas.93.1.65"},{"key":"2021121010073473000_R34","doi-asserted-by":"crossref","unstructured":"Hermans MM, De Graaff E, Kroos MA, et al. The effect of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II. Hum Mol Genet.\u20081994;3:2213\u20132218","DOI":"10.1093\/hmg\/3.12.2213"},{"key":"2021121010073473000_R35","doi-asserted-by":"crossref","unstructured":"Winkel LPF, Kamphoven JHJ, Van den Hout JMP, et al. Morphological changes in muscle tissue of patients with infantile Pompe\u2019s disease receiving enzyme replacement therapy. Muscle Nerve.\u20082003;27:743\u2013751","DOI":"10.1002\/mus.10381"},{"key":"2021121010073473000_R36","doi-asserted-by":"crossref","unstructured":"Vogel M, Staller W, Buhlmeyer K. Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants and children. Pediatr Cardiol.\u20081991;12:143\u2013149","DOI":"10.1007\/BF02238520"},{"key":"2021121010073473000_R37","doi-asserted-by":"crossref","unstructured":"Wisselaar HA, Kroos MA, Hermans MM, Van Beeumen J, Reuser AJ. Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem.\u20081993;268:2223\u20132231","DOI":"10.1016\/S0021-9258(18)53985-5"},{"key":"2021121010073473000_R38","doi-asserted-by":"crossref","unstructured":"Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial. Genet Med.\u20082001;3:132\u2013138","DOI":"10.1097\/00125817-200103000-00008"},{"key":"2021121010073473000_R39","doi-asserted-by":"crossref","unstructured":"Eng C, Guffon N, Wilcox W, et al. Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry\u2019s disease. N Engl J Med.\u20082001;345:9\u201316","DOI":"10.1056\/NEJM200107053450102"},{"key":"2021121010073473000_R40","doi-asserted-by":"crossref","unstructured":"Eng CM, Banikazemi M, Gordon RE, et al. A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet.\u20082001;68:711\u2013722","DOI":"10.1086\/318809"},{"key":"2021121010073473000_R41","doi-asserted-by":"crossref","unstructured":"Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev.\u20081998;12:115\u2013133","DOI":"10.1016\/S0268-960X(98)90023-6"},{"key":"2021121010073473000_R42","doi-asserted-by":"crossref","unstructured":"Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med.\u20082001;344:182\u2013188","DOI":"10.1056\/NEJM200101183440304"},{"key":"2021121010073473000_R43","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in Fabry disease. A randomized controlled trial. JAMA.\u20082001;285:2743\u20132749","DOI":"10.1001\/jama.285.21.2743"},{"key":"2021121010073473000_R44","unstructured":"Winkel LPF, Van den Hout JMP, Kamphoven JHJ, et al. Preliminary findings in patients with juvenile Pompe\u2019s disease treated with recombinant human alpha-glucosidase from rabbit milk. Am J Hum Genet.\u20082001;S96:674"},{"key":"2021121010073473000_R45","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Murray GJ, Treco D, et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A.\u20082000;97:365\u2013370","DOI":"10.1073\/pnas.97.1.365"},{"key":"2021121010073473000_R46","doi-asserted-by":"crossref","unstructured":"Sands MS, Vogler CA, Ohlemiller KK, et al. Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol Chem.\u20082001;276:43160\u201343165","DOI":"10.1074\/jbc.M107778200"},{"key":"2021121010073473000_R47","doi-asserted-by":"crossref","unstructured":"Raben N, Jatkar T, Lee A, et al. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol Ther.\u20082002;6:601\u2013608","DOI":"10.1006\/mthe.2002.0716"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/113\/5\/e448\/1003812\/zpe0050400e448.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/113\/5\/e448\/1003812\/zpe0050400e448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T22:27:38Z","timestamp":1639175258000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/113\/5\/e448\/66718\/Long-Term-Intravenous-Treatment-of-Pompe-Disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,1]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2004,5,1]]},"published-print":{"date-parts":[[2004,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.113.5.e448","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,1]]}}}